| Project/Area Number |
26670018
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Physical pharmacy
|
|---|
| Research Institution | University of Shizuoka |
|---|
Principal Investigator |
Oku Naoto 静岡県立大学, 薬学部, 教授 (10167322)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ASAI Tomohiro 静岡県立大学, 薬学部, 准教授 (00381731)
SHIMIZU Kosuke 静岡県立大学, 薬学部, 講師 (30423841)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 核酸医薬品 / RNA干渉 / ポリカチオンリポソーム / がん治療 / マイクロRNA / 血管正常化 / TEPA-PCL / miR499 / miR-499 / 腫瘍血管新生 / 併用療法 / ドキソルビシン / 新生血管標的化 |
|---|
| Outline of Final Research Achievements |
Previously, we clarified that miR-499 suppressed tumor growth through the inhibition of vascular endothelial growth factor (VEGF) production and subsequent angiogenesis. In this study, we focused on the genetic therapy using microRNA-499 (miR-499)in combination with chemotherapy for the advanced treatment of cancer.Firstly, tetraethylenepentamine-based polycation liposomes (TEPA-PCL) were prepared and modified with angiogenic vessel-targeted peptide for the delivery of miR-499 (APRPG-miR-499) to angiogenic vessels and tumor cells. The tumor blood flow was significantly improved, after systemic administration of APRPG-miR-499 to colon carcinoma-bearing mice. In addition, the accumulation of doxorubicin (DOX) in the tumors was increased by pre-treatment with APRPG-miR-499. Finally, the combination therapy of APRPG-miR-499 and DOX resulted in significant suppression of the tumor growth.
|
